Jaguar Health (JAGX) Research & Development (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Research & Development of $896000.0 for Q1 2026, down 64.06% year-over-year from $2.5 million in Q1 2025, and down 93.74% quarter-over-quarter from $14.3 million in Q4 2025.
Jaguar Health (JAGX) Research & Development (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Research & Development for 13 consecutive years, with $896000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 64.06% year-over-year to $896000.0; the TTM figure through Mar 2026 stood at $22.1 million (up 491.13% YoY), while the FY2025 annual figure was $25.0 million, up 224.57% from the prior year.
- Research & Development fell to $896000.0 in Q1 2026 per JAGX's latest filing, from $14.3 million in the prior quarter.
- Across five years, Research & Development topped out at $14.3 million in Q4 2025 and bottomed at -$8.7 million in Q4 2023.
- Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $3.3 million in 2025.
- Annual changes were most pronounced in 2023 — Research & Development plunged 301.18% — and 2025, when it surged 431.63%.
- Jaguar Health's Research & Development stood at $4.3 million in 2022, then tumbled by 301.18% to -$8.7 million in 2023, then soared by 50.24% to -$4.3 million in 2024, then soared by 431.63% to $14.3 million in 2025, then slumped by 93.74% to $896000.0 in 2026.
- Business Quant data shows JAGX's Research & Development at $896000.0 in Q1 2026, $14.3 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Jaguar Health | 452,552.38 | -9.61 Mn | 19.11 Mn | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 896,000.00 |
| Dec 31, 2025 | 14.31 Mn |
| Sep 30, 2025 | 3.66 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | -4.32 Mn |
| Sep 30, 2024 | 4.04 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | -8.67 Mn |
| Sep 30, 2023 | 6.08 Mn |
| Jun 30, 2023 | 1.57 Mn |
| Mar 31, 2023 | 4.78 Mn |
| Dec 31, 2022 | 4.31 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 2.14 Mn |
| Mar 31, 2022 | 4.95 Mn |
| Dec 31, 2021 | 8.48 Mn |
| Sep 30, 2021 | 2.26 Mn |
| Jun 30, 2021 | 3.87 Mn |